Therapeutic Solutions International Inc. (OTCMKTS:TSOI) is down 25% in a week. The company has announced filing an IND application with the FDA to commence StemVacs-V immunotherapy clinical studies in metastatic breast cancer patients.
In addition, therapeutic Solutions International announced on May 24, 2021, progress in preclinical trials supporting immunotherapy use in human trials. So far, part of the trials showed superior StemVacs-v activity compared to other immunotherapy approaches cleared by the FDA. Notably, StemVacs-V can “choke” cancer tumors to death through blood supply blocking.
The company’s Chief Medical Officer James Veltmeyer said he is delighted to lead the medical initiatives to bring the game-changing approach to breast cancer patients. He explained that previous efforts to create immunotherapy that can kill tumor blood vessels resulted in drugs like Avastin, which has limitations but generated multi-billion dollar sales annually. However, he said that the StemVacs-V approach had shown superiority over other approaches since it induced a more diverse and potent immune response targeting tumor blood vessels. Therefore, with StemVacs-V immunotherapy in clinical trials, TSOI is a stock investor should watch.
On Monday, TSOI stock jumped 1.36% at $0.0933 with more than 14.60 million shares, compared to its average volume of 13.80 million shares. The stock has moved within a range of $0.0882 – 0.0980 after opening the trade at $0.0900.